CING News and Press, Cingulate Inc. From 02/24/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Bridger Aerospace (NASDAQ: BAER ) stock is taking off on Friday after a filing revealed stakes in the company . According to the U.S. Securities and Exchange Commission (SEC) filing, JCIC Spo...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock Cingulate (NASDAQ: CING ) stock is on the rise Friday after releasing positive data concerning its ADHD treatment . The big news today is Cingulate’s CTx-1301 can be taken with or with...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: f11photo/Shutterstock.com It’s time to start off trading on Friday with a breakdown of the biggest pre-market stock movers worth keeping an eye on! Moving stocks this morning are earnings reports, clinica...

Cingulate ( NASDAQ: CING ) on Thursday reported what it deemed to be positive results from a study assessing its tablet formulation of dexmethylphenidate. Shares of the biopharmaceutical company soared more than 75% to $1.92 after hours. Dexmethylphenidate is a compound approv...

Primary Endpoints Demonstrate CTx-1301 Can be Taken With or Without Food CTx-1301 is Designed as a True, Entire Active-Day Treatment for ADHD KANSAS CITY, Kan., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its ...

Trial Results Expected 1H 2023 Company to Host Investor and Business Development Meetings Adjacent to Upcoming J.P. Morgan Healthcare Conference in San Francisco KANSAS CITY, Kan., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical co...

KANSAS CITY, Kan., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, tod...

Cingulate press release ( NASDAQ: CING ): Q3 GAAP EPS of -$0.36 beats by $0.01 . Cash and cash equivalents of $7.9M For further details see: Cingulate GAAP EPS of -$0.36 beats by $0.01

Phase 3 Trial Initiation for Lead ADHD Candidate CTx-1301 in December 2022 Executed Manufacturing Agreement with Societal CDMO 2022 Psych Congress Presentation Demonstrated Ability of Anxiety Candidate CTx-2103 to Deliver a Single Administration of Triple-Release Buspiro...

Kansas City, Kansas--(Newsfile Corp. - November 3, 2022) - Cingulate Inc. (NASDAQ: CING) , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical pr...